This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Inflammation				
Shock; trauma	Sphingosine-1-phosphate receptor 2 (S1PR2; S1P2; EDG5)	<i>In vitro</i> and mouse studies suggest that antagonizing S1P2 could help treat anaphylactic shock. In cord blood-derived mast cells, an S1P2 antagonist reduced S1P2- or antigen-mediated degranulation and cytokine release that contribute to anaphylactic shock. In a mouse model of anaphylactic shock, an S1P2 antagonist reduced symptoms including hypothermia and pulmonary edema compared with no treatment. Next steps could include testing the strategy in additional animal models.	Patent and licensing status unavailable	Oskeritzian, C. <i>et al. J. Exp. Med.</i> ; published online March 1, 2010; doi:10.1084/jem.20091513 Contact: Carole Oskeritzian, Virginia Commonwealth University, Richmond, Va. e-mail: coskerit@vcu.edu
SciBX 3(11); doi:10.1038/scibx.2010.349 Published online March 18, 2010				